3,500
Participants
Start Date
July 18, 2021
Primary Completion Date
June 30, 2027
Study Completion Date
June 30, 2027
DOAC
Patients will receive a DOAC at doses recommended for the indication, adjusted for their renal function is required. The choice of DOAC will be at the discretion of the treating physician.
VKA
Patients in the control group will receive VKA once daily; the individual dose will be titrated to achieve a guideline-recommended INR range.
NOT_YET_RECRUITING
Royal Melbourne Hospital, University of Melbourne, Parkville
RECRUITING
St Vincent's Hospital Melbourne, Fitzroy
RECRUITING
University Medical Center Hamburg-Eppendorf, Hamburg
NOT_YET_RECRUITING
West-German Heart and Vascular Center, University of Duisburg-Essen, Essen
ACTIVE_NOT_RECRUITING
University Hospital Bonn Heart Center, Bonn
RECRUITING
University of Alberta Hospital, Edmonton
RECRUITING
University of British Columbia, Vancouver
RECRUITING
St. Boniface Hospital, Winnipeg
ACTIVE_NOT_RECRUITING
Saint John Regional Hospital, Saint John
RECRUITING
Health Science Centre, St. John's
RECRUITING
Health Sciences North Research Institute, Greater Sudbury
RECRUITING
Hamilton General Hospital, Hamilton
RECRUITING
Sunnybrook Hospital, Toronto
RECRUITING
Toronto General Hospital, Toronto
RECRUITING
Montreal Heart Institute, Montreal
ACTIVE_NOT_RECRUITING
Hôpital Sacré-Coeur de Montréal, Montreal
RECRUITING
IUCPQ-ULaval, Québec
ACTIVE_NOT_RECRUITING
Heart Center Leipzig, Leipzig
RECRUITING
University Hospital Jena, Jena
Lead Sponsor
Hamilton Health Sciences Corporation
OTHER
Population Health Research Institute
OTHER